| ||||||||||||||
|
|
|||||||||||||

Departments of
*Anesthesiology and
Orthopedic Surgery, University of Cologne, Cologne, Germany
Address correspondence and reprint requests to Sandra Kampe, MD, Department of Anesthesiology, University of Cologne, Joseph-Stelzmann-Straße 9, 50931 Cologne, Germany.
| Abstract |
|---|
|
|
|---|
Implications: This is the first randomized study comparing the efficacy of the epidural combination of ropivacaine 0.1% and sufentanil 1 µg/mL versus plain ropivacaine 0.1% in treating pain after hip replacement. We found that ropivacaine 0.1% and sufentanil 1 µg/mL led to a sixfold reduction in opioid requirements after total hip replacement by producing a negligible motor block.
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
On arrival in the recovery room, an epidural infusion with either 0.1% ropivacaine or 0.1% ropivacaine and 1 µg/mL sufentanil was commenced at a rate calculated as follows: (height in centimeters -100) x 0.1.
All patients had access to IV piritramide, a commonly used opioid in Europe (6) with approximately half the potency of morphine, via a PCA device (Abbott Lifecare PCA Infusor; Abbott Laboratories, North Chicago, IL) with 1.5-mg bolus doses, a 6-min lockout time, and a 45-mg dose limit over 4 h.
Wound pain at rest and on coughing was assessed by using a 100-mm visual analog scale ranging from 0 (no pain) to 100 (worst pain imaginable). Sensory block was assessed bilaterally by using analgesia to pinprick with a short-beveled 27-gauge needle, and motor block was assessed according to a modified Bromage scale (7) (0 = no motor block, 1 = inability to raise extended legs, 2 = inability to flex knees, 3 = inability to flex ankle joints). All postoperative assessments at 4, 8, 16, 24, 32, 40, and 48 h were performed by one of the authors. PCA piritramide consumption was recorded. The quality of pain management was judged by the patients and recorded at the last assessment on a 4-point scale (1 = poor, 2 = fair, 3 = good, 4 = excellent). Monitoring included noninvasive blood pressure, heart rate, and respiratory rate. Hypotension was defined as systolic blood pressure <80 mm Hg or >30% decrease compared with baseline; hypertension was defined as blood pressure >180 mm Hg systolic or 110 mm Hg diastolic; bradycardia was defined as heart rate <50 bpm; and tachycardia was defined as heart rate >120 bpm (2,3). Bradypnea was defined as a respiratory rate <12 breaths/min and tachypnea was defined as a respiratory rate >20 breaths/min. Sedation was recorded on a 4-point scale (0 = no signs of sedation, 1 = mild sedation, 2 = moderate sedation, 3 = severe sedation). The incidence of nausea and vomiting was recorded.
Statistical analysis was performed using the SPSS statistical package (SPSS Inc., Chicago, IL). Because there were no available data on piritramide consumption under similar circumstances, it was not possible to calculate sample size in advance with respect to statistical power.
PCA piritramide consumption was compared in a paired manner using the two-tailed Wilcoxon rank sum test. Differences were considered statistically signifiant at P < 0.05. Demographic data are presented descriptively. Data are presented as the means ± SD.
| Results |
|---|
|
|
|---|
The two groups did not differ in demographic data (Table 1).
|
The R+S group required 6 times less piritramide than the R group over 48 h (P < 0.001) (Fig. 1). The R+S group used less than half the piritramide as the R group (P < 0.05) in the first 8 h after beginning the epidural infusion; at 16 h, the R+S group required 3 times less piritramide than the R group (P < 0.001) (Fig. 1). The R+S group had a minimal, but constant, piritramide use over the study period, whereas the R group had peak uses at 1624 h and a decrease after that.
|
Two patients in the R group had pain scores of 2040 mm at rest and on coughing 4 h after starting the epidural infusion, and one patient had pain scores of 50 mm at rest and on coughing 16 h after the start of the infusion.
Motor block resolved rapidly in both groups. Four patients in the R+S group showed a Bromage grade 1 motor block, and three patients showed a grade 2 motor block 4 h after beginning the epidural infusion. One patient had a grade 1 motor block after 8 h.
In the R group, two patients experienced a grade 2 motor block at 4 h, and one patient had a grade 3 motor block in his left leg and a grade 2 motor block in his right leg.
Sensory block regressed equally in both groups. The sensory block was still at T10 within 4 h after starting the continuous infusion in two patients in each group. After 8 h of epidural infusion, sensory block had completely regressed.
All patients rated the quality of pain management as excellent or good.
Nausea was experienced by five patients (four female, one male) in the R+S group, with all women experiencing vomiting. In the R group, two patients (one male, one female) had nausea.
Four patients (two male, two female) in the R group had mild to moderate sedation, whereas just one patient in the R+S group was moderately sedated.
One patient from each group experienced pruritus.
Most side effects were mild and except for the administration of IV metoclopramide for nausea, no other specific treatment was required.
| Discussion |
|---|
|
|
|---|
We found that the epidural combination of ropivacaine with sufentanil for postoperative pain relief after THR caused a sixfold reduction in analgesic requirements over 48 h without motor blockade. Although theoretical advantages for adding lipophilic drugs to epidural local anesthetics have been postulated (8,9), the risk/benefit analysis of this techniquecompared with epidural opioids alone or IV PCA opioidsis controversial (10,11). Our study does not resolve, nor was it specially designed to address, these issues, and this detracts from its clinical usefulness.
The longest period of observation in comparable ropivacaine studies was 21 hours (2,3). Our observation period allowed us to identify differences reliably in opioid requirements and in the degree of sensory and motor blockades in both study groups. The prolonged duration of ropivacaine 0.75% given intraoperatively is the most likely explanation for the sensory (4 of 30) and motor blockades (7 of 30) seen four hours postoperatively. The low pain scores in our study were almost certainly due to the type of surgery. THR is thought to be less painful than abdominal and knee surgery. Total knee replacement often causes severe pain on motion that requires different local anesthetic concentrations.
Like bupivacaine (12), ropivacaine causes hypotension in a dose-dependent manner (2). The absence of hypotension in our study is most likely due to the low concentration of ropivacaine used. We observed twice as much nausea and vomiting in the R+S group compared with the R group. It would require further studies with a much larger number of patients to determine whether the incidence of nausea and vomiting with R+S, compared with plain R, would reach statistical significance.
In summary, we showed that the combination of ropivacaine 0.1% with sufentanil 1 µg/mL is a safe technique for postoperative analgesia after THR, causing no motor weakness and requiring only minimal analgesic supplementation in the first 48 hours.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. K. Kim, S. B. Nam, M. J. Cho, and Y.-S. Shin Epidural naloxone reduces postoperative nausea and vomiting in patients receiving epidural sufentanil for postoperative analgesia Br. J. Anaesth., August 1, 2007; 99(2): 270 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kampe, C. Poetter, S. Buzello, H.-M. Wenchel, M. Paul, P. Kiencke, and S.-M. Kasper Ropivacaine 0.1% with Sufentanil 1 {micro}g/mL Inhibits In Vitro Growth of Pseudomonas Aeruginosa and Does Not Promote Multiplication of Staphylococcus Aureus Anesth. Analg., August 1, 2003; 97(2): 409 - 411. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kampe, P. Kiencke, A. Delis, M. Auweiler, D. P. Konig, and S.-M. Kasper The continuous epidural infusion of ropivacaine 0.1% with 0.5 {micro}g*mL-1 sufentanil provides effective postoperative analgesia after total hip replacement: a pilot study: [La perfusion continue de ropivacaine a 0,1 % additionnee de 0,5 {micro}g*mL-1 de sufentanil produit une analgesie postoperatoire efficace apres l'arthroplastie totale de hanche : une etude pilote] Can J Anesth, June 1, 2003; 50(6): 580 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kampe, P. Kiencke, J. Krombach, K. Cranfield, S. M. Kasper, and C. Diefenbach Current Practice in Postoperative Epidural Analgesia: A German Survey Anesth. Analg., December 1, 2002; 95(6): 1767 - 1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Senard, J. L. Joris, D. Ledoux, P. J. Toussaint, B. Lahaye-Goffart, and M. L. Lamy A Comparison of 0.1% and 0.2% Ropivacaine and Bupivacaine Combined with Morphine for Postoperative Patient-Controlled Epidural Analgesia After Major Abdominal Surgery Anesth. Analg., August 1, 2002; 95(2): 444 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kampe and F. Singelyn Extended Femoral Nerve Sheath Block After Total Hip Arthroplasty Response Anesth. Analg., September 1, 2001; 93(3): 804 - 804. [Full Text] [PDF] |
||||
![]() |
R. G. Wheatley, S. A. Schug, and D. Watson Safety and efficacy of postoperative epidural analgesia Br. J. Anaesth., July 1, 2001; 87(1): 47 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Brodner, N. Mertes, H. Van Aken, T. Mollhoff, M. Zahl, S. Wirtz, M. A. E. Marcus, and H. Buerkle What Concentration of Sufentanil Should be Combined with Ropivacaine 0.2% wt/vol for Postoperative Patient-Controlled Epidural Analgesia? Anesth. Analg., March 1, 2000; 90(3): 649 - 657. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|